natgillin/translations-raw huggingface dataset:
Simulations suggest that the prolonged dose interval is not optimal and could result in increased toxicity and possibly inadequate response.
Simulacije nakazujejo, da podaljšani odmerni interval ni optimalen in lahko vodi v povečano toksičnost in možnost nezadostnega odziva.
Therefore clinical response to treatment and renal function should be closely monitored (see sections 4.4 and 5.2).
3 Zato je potrebno pri teh bolnikih skrbno nadzorovati klinični odziv na zdravljenje in delovanje ledvic (glejte poglavji 4. 4 in 5. 2).
3 * Generally, once weekly dosing assuming three haemodialysis sessions per week, each of approximately 4 hours duration or after 12 hours cumulative haemodialysis.
1 odmerek enkrat tedensko pri predpostavljenih treh hemodializah na teden, vsaka po približno 4 ure ali skupno 12 ur.
No dosing recommendations can be given for non-haemodialysis patients with creatinine clearance < 10 ml/ min.
Za bolnike z očistkom kreatinina < 10 ml/ min, ki niso na hemodializi, ni mogoče podati priporočil za odmerjanje.
No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
Pri bolnikih z motnjami v delovanju jeter ni potrebno prilagajanje odmerkov (glejte poglavji 4. 4 in 5. 2).
If Viread is discontinued in patients with chronic hepatitis B with or without HIV co-infection, these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4).
Če se jemanje zdravila Viread prekine pri bolnikih s kroničnim hepatitisom B s sočasno okužbo z virusom HIV ali brez nje, je treba pri teh bolnikih skrbno nadzorovati znake poslabšanja hepatitisa (glejte poglavje 4. 4).
Tenofovir disoproxil fumarate has not been studied in patients under the age of 18 or in patients over the age of 65.
Tenofovirdizoproksil fumarata niso proučevali pri bolnikih, mlajših od 18 let, ali pri bolnikih, starejših od 65 let.
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with tenofovir disoproxil fumarate (see below).
Verjetnost, da je ledvična funkcija pri starejših bolnikih zmanjšana, je večja, zato je pri zdravljenju starejših bolnikov s tenofovirdizoproksil fumaratom potrebna previdnost (glejte spodaj).
HIV antibody testing should be offered to all HBV infected patients before initiating tenofovir disoproxil fumarate therapy (see below Co-infection with HIV-1 and hepatitis B).
Pred začetkom zdravljenja s tenofovirdizoproksil fumaratom je treba testiranje prisotnosti protiteles proti virusu HIV predlagati vsem bolnikom, okuženim z virusom HBV (glejte spodaj Sočasna okužba z virusom HIV- 1 in virusom hepatitisa B).
Patients must be advised that tenofovir disoproxil fumarate has not been proven to prevent the risk of transmission of HIV or HBV to others through sexual contact or contamination with blood.
Bolniki morajo biti poučeni o tem, da zdravljenje s tenofovirdizoproksil fumaratom ne preprečuje tveganja za prenos HIV ali HBV na druge preko spolnega stika ali okužbe s krvjo.
Viread contains lactose monohydrate.
Viread vsebuje laktozo monohidrat.
Co-administration of other medicinal products:
Sočasna uporaba z drugimi zdravili:
- Viread should not be administered with any other medicinal products containing tenofovir
- Zdravila Viread se ne sme uporabljati z nobenimi drugimi zdravili, ki vsebujejo
disoproxil fumarate (Truvada or Atripla).
tenofovirdizoproksil fumarat (Truvada ali Atripla).
- Viread should also not be administered concurrently with adefovir dipivoxil.
- Zdravila Viread se prav tako ne sme uporabljati skupaj z adefovirdipivoksilom.
- Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended.
Sočasna uporaba
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse events (see section 4.5).
tenofovirdizoproksil fumarata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40- 60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4. 5).
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i. e. active) didanosine.
Sočasna uporaba tenofovirdizoproksil fumarata in didanozina pri odmerku 400 mg na dan je bila povezana s pomembnim zmanjšanjem števila celic CD4, morda zaradi znotrajcelične interakcije, ki je povečala količino fosforiliranega (to je aktivnega) didanozina.
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Sočasno zdravljenje z zmanjšanim odmerkom didanozina (250 mg) in tenofovirdizoproksil fumaratom je bilo v več preizkušenih kombinacijah za zdravljenje okužbe z virusom HIV- 1 povezano s poročili o visoki stopnji virološkega neuspeha.
Triple therapy with nucleosides/ nucleotides:
Tritirno zdravljenje z nukleozidi/ nukleotidi:
There have been reports of a high rate of virological failure and of emergence of resistance at early stage in HIV patients when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.
Obstajajo poročila o visoki stopnji virološkega neuspeha in pojavu rezistence, v obeh primerih v zgodnji fazi okužbe z virusom HIV, pri zdravljenju s kombinacijo tenofovirdizoproksil fumarata z lamivudinom in abakavirom kakor tudi z lamivudinom in didanozinom pri odmerjanju enkrat na dan.
Renal function:
4 Delovanje ledvic:
4 Renal safety with tenofovir has only been studied to a very limited degree in patients with impaired renal function (CrCl < 80 ml/ min).
Varnost uporabe tenofovirja za ledvice je bila pri bolnikih z oslabljenim delovanjem ledvic (CLCR < 80 ml/ min) preučevana le v zelo omejenem obsegu.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with tenofovir disoproxil fumarate and renal function (creatinine clearance and serum phosphate) is also monitored every four weeks during the first year, and then every three months.
Pred začetkom zdravljenja s tenofovirdizoproksil fumaratom se priporoča izračun očistka kreatinina pri vseh bolnikih in nadzor delovanja ledvic (očistek kreatinina in vrednost serumskega fosfata) vsake štiri tedne v prvem letu zdravljenja in pozneje vsake tri mesece.
Patients with creatinine clearance < 50 ml/ min, including haemodialysis patients:
Bolniki z očistkom kreatinina < 50 ml/ min, vključno z bolniki na hemodializi:
There are limited data on the safety and efficacy of tenofovir disoproxil fumarate in patients with impaired renal function.
Podatki o varnosti in učinkovitosti tenofovirdizoproksil fumarata pri bolnikih z oslabljenim delovanjem ledvic so pomankljivi.
Therefore, tenofovir disoproxil fumarate should only be used if the potential benefits of treatment are considered to outweigh the potential risks.
Zato se sme tenofovirdizoproksil fumarat uporabljati samo, če se oceni, da morebitne koristi zdravljenja odtehtajo morebitna tveganja.
In patients with severe renal impairment (creatinine clearance < 30 ml/ min) use of tenofovir is not recommended.
Pri bolnikih s hudimi motnjami v delovanju ledvic (očistek kreatinina < 30 ml/ min) uporaba tenofovirja ni priporočljiva.
If no alternative treatment is available, the dosing interval must be adjusted and renal function should be closely monitored (see sections 4.2 and 5.2).
Če alternativne oblike zdravljenja ni na razpolago, je treba interval med odmerki prilagoditi, delovanje ledvic pa skrbno nadzorovati (glejte poglavji 4. 2 in 5. 2).
If serum phosphate is < 1.5 mg/ dl (0.48 mmol/ l) or creatinine clearance is decreased to < 50 ml/ min in any patient receiving tenofovir disoproxil fumarate, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Če je pri katerem koli bolniku, ki prejema tenofovirdizoproksil fumarat, vrednost serumskega fosfata < 1, 5 mg/ dl (0, 48 mmol/ l) ali se očistek kreatinina zmanjša na < 50 ml/ min, je potrebno ponovno ovrednotiti ledvično funkcijo v roku enega tedna, vključno z merjenjem koncentracije glukoze in kalija v krvi ter glukoze v urinu (glejte poglavje 4. 8, proksimalna tubulopatija).
Consideration should also be given to interrupting treatment with tenofovir disoproxil fumarate in patients with creatinine clearance decreased to < 50 ml/ min or decreases in serum phosphate to < 1.0 mg/ dl (0.32 mmol/ l).
Pri bolnikih z zmanjšanjem očistka kreatinina na < 50 ml/ min ali z zmanjšanjem serumskega fosfata na < 1, 0 mg/ dl (0, 32 mmol/ l) je treba presoditi tudi o prekinitvi zdravljenja s tenofovirdizoproksil fumaratom.
Use of tenofovir disoproxil fumarate should be avoided with concurrent or recent use of a nephrotoxic medicinal product (e. g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2).
Tenofovirdizoproksil fumarata naj ne bi uporabljali sočasno oziroma neposredno po uporabi nefrotoksičnih zdravil (npr. aminoglikozidi, amfotericin B, foskarnet, ganciklovir, pentamidin, vankomicin, cidofovir ali interlevkin- 2).
If concomitant use of tenofovir disoproxil fumarate and nephrotoxic agents is unavoidable, renal function should be monitored weekly.
Če je sočasna uporaba tenofovirdizoproksil fumarata in nefrotoksičnega zdravila neizogibna, je potrebno tedensko nadzorovati ledvično funkcijo.
Tenofovir disoproxil fumarate has not been clinically evaluated in patients receiving medicinal products which are secreted by the same renal pathway, including the transport proteins human organic anion transporter (hOAT) 1 and 3 or MRP 4 (e. g. cidofovir, a known nephrotoxic medicinal product).
Uporaba tenofovirdizoproksil fumarata klinično ni bila ovrednotena pri bolnikih, ki so prejemali zdravila, ki se izločajo po isti ledvični metabolni poti, vključno s transportnimi beljakovinami hOAT (human organic anion transporter) 1 in 3 ali MRP 4 (npr. cidofovir, znano nefrotoksičeno zdravilo).
Consequently, the pharmacokinetics of these medicinal products which are secreted by the same renal pathway including transport proteins hOAT 1 and 3 or MRP 4 might be modified if they are co-administered.
Tako lahko pri sočasnem jemanju teh zdravil, ki se izločata po isti ledvični metabolni poti, vključno s transportnimi beljakovinami hOAT 1 in 3 ali MRP 4, pride do spremembe njunih farmakokinetičnih lastnosti.
Unless clearly necessary, concomitant use of these medicinal products which are secreted by the same renal pathway is not recommended, but if such use is unavoidable, renal function should be monitored weekly (see section 4.5).
V takem primeru je potrebno nadzirati ledvično funkcijo tedensko (glejte poglavje 4. 5).
In HIV infected patients, in a 144-week controlled clinical study that compared tenofovir disoproxil fumarate with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve patients, small decreases in bone mineral density of the hip and spine were observed in both treatment groups.
V 144 tednov trajajoči kontrolirani klinični študiji, v kateri sta bila primerjana tenofovirdizoproksil fumarat in stavudin v kombinaciji z lamivudinom in efavirenzom pri bolnikih, okuženih z virusom HIV, ki še niso bili zdravljeni s protiretrovirusnimi zdravili, so pri obeh zdravljenih skupinah opazili manjše zmanjšanje mineralne gostote kosti kolka in hrbtenice.
Decreases in bone mineral density of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Zmanjšanje mineralne gostote kosti hrbtenice in spremembe kostnih biomarkerjev od začetne vrednosti so bile v 144. tednu pomembno večje v skupini, ki se je zdravila s tenofovirdizoproksil fumaratom.
Decreases in bone mineral density of hip were significantly greater in this group until 96 weeks.
Zmanjšanje mineralne gostote kosti v kolku je bilo do 96. tedna značilno večje v tej skupini.
Bone abnormalities (infrequently contributing to fractures) may be associated with proximal renal tubulopathy (see section 4.8).
5 Anomalije na kosteh (redko prispevajo k zlomom) so lahko povezane s proksimalno ledvično tubulopatijo (glejte poglavje 4. 8).
The safety of tenofovir in patients with decompensated liver disease is being studied.
Varnost tenofovira pri bolnikih z dekompenzirano jetrno boleznijo še raziskujejo.
At present the safety in this patient population has not been thoroughly evaluated.
Varnost pri tej populaciji bolnikov še ni popolnoma ovrednotena.
No safety and efficacy data are available in liver transplant patients.
Podatki o varnosti in učinkovitosti pri bolnikih s presajenimi jetri še niso na voljo.
5 Exacerbations of hepatitis:
Eksacerbacije hepatitisa:
Flares on treatment:
Poslabšanje med zdravljenjem:
Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT.
Spontane eksacerbacije kroničnega hepatitisa B so sorazmerno običajne, zanje pa so značilna prehodna zvišanja ALT v serumu.
After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline (see section 4.8).
Po uvedbi protivirusnega zdravljenja se lahko serumske vrednosti ALT pri nekaterih bolnikih povečajo, medtem ko se serumske vrednosti HBV DNA zmanjšajo (glejte poglavje 4. 8).
Among tenofovir-treated patients on-treatment exacerbations typically occurred after 4-8 weeks of therapy.
Pri bolnikih, zdravljenih s tenofovirjem, so se eksacerbacije med zdravljenjem navadno pojavile po 4 do 8 tednih zdravljenja.
Patients with cirrhosis may be at a higher risk for hepatic decompensation following hepatitis exacerbation, and therefore should be monitored closely during therapy.
Bolniki s cirozo so lahko bolj izpostavljeni tveganju za jetrno dekompenzacijo po eksacerbaciji hepatitisa, zato jih je treba med zdravljenjem skrbno nadzorovati.
Flares after treatment discontinuation:
Poslabšanje po prenehanju zdravljenja:
Acute exacerbation of hepatitis has also been reported in patients who have discontinued hepatitis B therapy.
O akutni eksacerbaciji hepatitisa so poročali tudi pri bolnikih, ki so prekinili zdravljenje hepatitisa B.
Post-treatment exacerbations are usually associated with rising HBV DNA, and the majority appears to be self-limited.
Eksacerbacije po zdravljenju so po navadi povezane z zvišanjem ravni HBV DNA, večina eksacerbacij pa mine spontano.
However, severe exacerbations, including fatalities, have been reported.
Vendar pa so poročali tudi o hudih eksacerbacijah, vključno s smrtnimi primeri.
Hepatic function should be monitored at repeated intervals with both clinical and laboratory follow-up for at least 6 months after discontinuation of hepatitis B therapy.
Delovanje jeter je treba spremljati v rednih intervalih s kliničnimi in laboratorijskimi preiskavami vsaj še nadaljnjih 6 mesecev po prekinitvi zdravljenja proti hepatitisu B.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Pri bolnikih z napredovalo boleznijo jeter ali cirozo, prekinitev zdravljenja ni priporočena, saj eksacerbacije hepatitisa po zdravljenju lahko povzročijo jetrno dekompenzacijo.
Co-infection with hepatitis C or D:
Sočasna okužba s hepatitisom C ali D:
There are no data on the efficacy of tenofovir in patients co-infected with hepatitis C or D virus.
Podatkov o učinkovitosti tenofovirja pri bolnikih s sočasno okužbo z virusom hepatitisa C ali D ni.
Co-infection with HIV-1 and hepatitis B:
Sočasna okužba z virusom HIV- 1 in virusom hepatitisa B:
Due to the risk of development of HIV resistance, tenofovir disoproxil fumarate should only be used as part of an appropriate antiretroviral combination regimen in HIV/ HBV co-infected patients.
Zaradi tveganja za nastanek odpornosti virusa HIV se sme tenofovirdizoproksil fumarat pri bolnikih, okuženih z virusoma HIV/ HBV, uporabljati samo kot del ustreznega režima kombiniranega protiretrovirusnega zdravljenja.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Bolniki s predobstoječo jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije več anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.
However, it should be noted that increases of ALT can be part of HBV clearance during therapy with tenofovir, see above Exacerbations of hepatitis.
Glejte “ Eksacerbacije hepatitisa ” zgoraj.
Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues.
Pri uporabi analogov nukleozidov so poročali o laktacidozi, ki je običajno združena z jetrno steatozo.
The preclinical and clinical data suggest that the risk of occurrence of lactic acidosis, a class effect of nucleoside analogues, is low for tenofovir disoproxil fumarate.
Predklinični in klinični podatki nakazujejo, da je tveganje za pojav laktacidoze (tipičen učinek analogov nukleozidov) nizko pri uporabi tenofovirdizoproksil fumarata.
However, as tenofovir is structurally related to nucleoside analogues, this risk cannot be excluded.
Kljub temu pa se zaradi strukturne sorodnosti tenofovirja analogom nukleozidov tveganja ne da izključiti.
Early symptoms (symptomatic hyperlactatemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/ or deep breathing) or neurological symptoms (including motor weakness).
Zgodnji simptomi (simptomatska hiperlaktatemija) vključujejo benigne prebavne simptome (navzea, bruhanje in abdominalno bolečino), nespecifično slabo počutje, izgubo apetita, izgubo teže, respiratorne simptome (hitro in/ ali globoko dihanje) ali nevrološke simptome (vključujoč motorično oslabelost).
Lactic acidosis has a high mortality and may be associated with pancreatitis, liver failure or renal failure.
Laktacidozo spremlja visoka smrtnost in je lahko združena s pankreatitisom, jetrno ali ledvično odpovedjo.
Lactic acidosis generally occurred after a few or several months of treatment.
Laktacidoza se je običajno pojavila po nekaj ali več mesečnem zdravljenju.
Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.
Zdravljenje z analogi nukleozidov je treba prekiniti, če pride do simptomatske hiperlaktatemije in metabolične acidoze/ laktacidoze, napredujoče hepatomegalije ali hitro naraščajočega nivoja aminotransferaz.
Caution should be exercised when administering nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol).
6 Previdnost je potrebna, če dajemo analoge nukleozidov kateremukoli bolniku (še posebej ženskam s prekomerno težo) s hepatomegalijo, hepatitisom ali drugimi znanimi dejavniki tveganja za jetrne bolezni in jetrno steatozo (vključno z določenimi zdravili in alkoholom).
Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Bolniki s sočasno okužbo s hepatitisom C, zdravljeni z alfa interferonom in ribavirinom lahko predstavljajo posebno tveganje.
Patients at increased risk should be followed closely.
Bolnike s povečanim tveganjem moramo skrbno spremljati.
Lipodystrophy (lipoatrophy/ lipomatosis):
Lipodistrofija (lipoatrofija/ lipomatoza):
In HIV infected patients, combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy).
Kombinirana protiretrovirusna terapija pri bolnikih, okuženih z virusom HIV, je povezana s prerazporeditvijo telesne maščobe (lipodistrofija).
The long-term consequences 6 of these events are currently unknown.
Dolgoročne posledice teh pojavov trenutno niso poznane.
A connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.
Postavljena je hipoteza o povezanosti med visceralno lipomatozo in zaviralci proteaze in med lipoatrofijo in nukleozidnimi zaviralci reverzne transkriptaze.
However, 144-week clinical data from antiretroviral-naïve HIV infected patients indicate that the risk of lipodystrophy was lower with tenofovir disoproxil fumarate than with stavudine when administered with lamivudine and efavirenz.
Vendar pa klinični podatki iz 144 tednov pri bolnikih, okuženih z virusom HIV, ki še niso bili zdravljeni s protiretrovirusnimi zdravili, kažejo, da je tveganje za lipodistrofijo manjše, če je bil tenofovirdizoproksil fumarat zaužit z lamivudinom in efavirenzom kot pri stavudinu v kombinaciji z lamivudinom in efavirenzom.
Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterium infections, and Pneumocystis jiroveci pneumonia.
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ ali žariščne okužbe z mikobakterijami in s Pneumocystis jiroveci povzročena pljučnica.
Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low.
7 Na osnovi rezultatov z in vitro preizkusov in glede na znano pot izločanja tenofovirja je možnost za s CYP450 posredovano interakcijo tenofovirja z drugimi zdravili majhna.
Concomitant use not recommended:
Odsvetovane kombinacije z drugimi zdravili:
Viread should not be administered with any other medicinal products containing tenofovir disoproxil fumarate (Truvada or Atripla).
Zdravila Viread se ne sme uporabljati z nobenimi drugimi zdravili, ki vsebujejo tenofovirdizoproksil fumarat (Truvada ali Atripla).
Viread should also not be administered concurrently with adefovir dipivoxil.
Zdravila Viread se prav tako ne sme uporabljati skupaj z adefovirdipivoksilom.
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4 and Table 1).
Sočasna uporaba tenofovirdizoproksil fumarata in didanozina ni priporočena (glejte poglavje 4. 4 in preglednico 1).
7 Renally eliminated medicinal products:
Zdravila, ki se izločajo preko ledvic:
Since tenofovir is primarily eliminated by the kidneys, co-administration of tenofovir disoproxil fumarate with medicinal products that reduce renal function or compete for active tubular secretion via transport proteins hOAT 1, hOAT 3 or MRP 4 (e. g. cidofovir) may increase serum concentrations of tenofovir and/ or the co-administered medicinal products.
Tenofovir se izloča predvsem preko ledvic, zato lahko sočasna uporaba tenofovirdizoproksil fumarata in zdravil, ki zmanjšujejo delovanje ledvic ali tekmujejo za aktivno tubularno sekrecijo preko transportnih beljakovin hOAT 1, hOAT 3 ali MRP 4 (npr. cidofovir), poveča serumske koncentracije tenofovirja in/ ali sočasno uporabljenih zdravil.
Some examples include, but are not limited to, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (see section 4.4).
Nekateri primeri vključujejo aminoglikozide, amfotericin B, foskarnet, ganciklovir, pentamidin, vankomicin, cidofovir ali interlevkin- 2, vendar pa niso omejeni nanje (glejte poglavje 4. 4).
Given that tacrolimus can affect renal function, close monitoring is recommended when it is co-administered with tenofovir disoproxil fumarate.
Takrolimus lahko vpliva na delovanje ledvic, zato je ob sočasni uporabi takrolimusa in tenofovirdizoproksil fumarata priporočeno skrbno nadzorovati bolnika.